Publications
- Overcoming resistance to rituximab in relapsed non-Hodgkin lymphomas by antibody-polymer drug conjugates actively targeted by anti-CD38 daratumumab2020 | First Faculty of Medicine
- Complex genetic and histopathological study of 15 patient-derived xenografts of aggressive lymphomas2022 | First Faculty of Medicine, Second Faculty of Medicine, Faculty of Medicine in Pilsen, Faculty of Physical Education and Sport
- Anti-apoptotic MCL1 Protein Represents Critical Survival Molecule for Most Burkitt Lymphomas and BCL2-negative Diffuse Large B-cell Lymphomas2022 | First Faculty of Medicine
- Quantitative In Vivo Monitoring of Hypoxia and Vascularization of Patient-Derived Murine Xenografts of Mantle Cell Lymphoma Using Photoacoustic and Ultrasound Imaging2021 | First Faculty of Medicine, Faculty of Medicine in Pilsen
- Cytarabine nanotherapeutics with increased stability and enhanced lymphoma uptake for tailored highly effective therapy of mantle cell lymphoma2021 | First Faculty of Medicine
- Anti-CD38 Therapy with Daratumumab for Relapsed/Refractory CD20-Negative Diffuse Large B-Cell Lymphoma2020 | First Faculty of Medicine, Second Faculty of Medicine
- Cotargeting of BCL2 with venetoclax and MCL1 with S63845 is synthetically lethal in vivo in relapsed mantle cell lymphoma2019 | First Faculty of Medicine, Second Faculty of Medicine
- Effective doxorubicin-based nano-therapeutics for simultaneous malignant lymphoma treatment and lymphoma growth imaging2018 | First Faculty of Medicine
Loading network view...